[Effect of 6-keto prostaglandin E1 on the ascitic hepatoma-130 in vivo. Comparison with chemotherapeutic agent].
The effect of 6-keto-prostaglandin E1 which has a potential action for antiplatelet aggregation was investigated against AH-130 in vivo in comparison with mitomycin C. The experimental schemes were as follows: Group I: Control, Group II: Thromboxane B2 (0.5 mg/kg, X 8, iv), Group III: 6-keto-PG-E1 (0.5 mg/kg, X 10, iv), Group IV: MMC (1.5 mg/kg, X 1, ip), Group V: 6-keto-PGE1 + MMC (0.5 mg/kg, X 10, iv, + 1.5 mg/kg, X 1, ip). The mean survival days, median survival day, and ILS% for 60 days disclosed an inhibitory effect of 6-keto-PGE1, 6-keto-PGE1 + MMC on AH-130 tumor cell growth. By contrast, TXB2, had a promoting effect on AH-130 tumor cell growth. It is concluded that 6-keto-PGE1 which has a structure activity relationship with antitumor agents, such as MMC, Diketocoriolin B, etc., played an important inhibitory role in tumor cell growth in AH-130 in vivo, particularly in combination with the antitumor agents, MMC.
D000527:Alprostadil / Q000031:analogs & derivatives*; D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D002479:Inclusion Bodies / Q000648:ultrastructure; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D008247:Lysosomes / Q000648:ultrastructure; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage / Q000627:therapeutic use*; D011458:Prostaglandins E / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D013329:Structure-Activity Relationship
D008937:Mitomycins; D011458:Prostaglandins E; D016685:Mitomycin; C022950:6-ketoprostaglandin E1; D000527:Alprostadil